650 related articles for article (PubMed ID: 28434150)
1. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
2. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
3. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
4. High-sensitivity cardiac troponin I detection for 2 types of drug-induced cardiotoxicity in patients with breast cancer.
Mokuyasu S; Suzuki Y; Kawahara E; Seto T; Tokuda Y
Breast Cancer; 2015 Nov; 22(6):563-9. PubMed ID: 24563373
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
[TBL] [Abstract][Full Text] [Related]
6. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.
Kang Y; Xu X; Cheng L; Li L; Sun M; Chen H; Pan C; Shu X
Eur J Heart Fail; 2014 Mar; 16(3):300-8. PubMed ID: 24464946
[TBL] [Abstract][Full Text] [Related]
7. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
8. [Early detection of the cardiotoxicity induced by chemotherapy drug through two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T].
Wang W; Kang Y; Shu XH; Shen XD; He B
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):835-840. PubMed ID: 29151290
[No Abstract] [Full Text] [Related]
9. Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab.
Canale ML; Casolo G; Donati S; Bisceglia I; Puccetti C; Amoroso D; Venturini E; Maurea N; Turazza FM; Camerini A
In Vivo; 2023; 37(5):2139-2146. PubMed ID: 37652487
[TBL] [Abstract][Full Text] [Related]
10. Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT.
Zhang CJ; Pei XL; Song FY; Guo Y; Zhang QL; Shu XH; Hsi DH; Cheng LL
Echocardiography; 2017 Nov; 34(11):1593-1600. PubMed ID: 28942608
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
[TBL] [Abstract][Full Text] [Related]
12. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
[TBL] [Abstract][Full Text] [Related]
13. Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy.
Tzolos E; Adamson PD; Hall PS; Macpherson IR; Oikonomidou O; MacLean M; Lewis SC; McVicars H; Newby DE; Mills NL; Lang NN; Henriksen PA
Clin Oncol (R Coll Radiol); 2020 May; 32(5):292-297. PubMed ID: 31813662
[TBL] [Abstract][Full Text] [Related]
14. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
[TBL] [Abstract][Full Text] [Related]
15. [Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab].
Pistillucci G; Ciorra AA; Sciacca V; Raponi M; Rossi R; Veltri E
Clin Ter; 2015; 166(1):e67-71. PubMed ID: 25756270
[TBL] [Abstract][Full Text] [Related]
16. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
Matos E; Jug B; Blagus R; Zakotnik B
Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
[TBL] [Abstract][Full Text] [Related]
17. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
[TBL] [Abstract][Full Text] [Related]
18. Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors.
Serrano JM; Mata R; González I; Del Castillo S; Muñiz J; Morales LJ; Espinosa MJ; Moreno F; Jiménez R; Cristobal C; Graupner C; Talavera P; Landaluce CG; Curcio A; Alonso J; Guerra JA; Alonso JJ
Int J Cardiol; 2023 Jul; 382():52-59. PubMed ID: 37080467
[TBL] [Abstract][Full Text] [Related]
19. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Ponde N; Bradbury I; Lambertini M; Ewer M; Campbell C; Ameels H; Zardavas D; Di Cosimo S; Baselga J; Huober J; Izquierdo M; Fumagalli D; Bozovic-Spasojevic I; Maetens M; Harbeck N; Pusztai L; Berghorn M; Im YH; Borrego MR; Chen DR; Rodeheffer R; Piccart M; Suter T; de Azambuja E
Breast Cancer Res Treat; 2018 Apr; 168(3):631-638. PubMed ID: 29280043
[TBL] [Abstract][Full Text] [Related]
20. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
Kotwinski P; Smith G; Cooper J; Sanders J; Ma L; Teis A; Kotwinski D; Mythen M; Pennell DJ; Jones A; Montgomery H;
PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]